Novartis Ag (NVS) FCF Margin Growth (1y) (2010 - 2024)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Margin Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
1,396.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-935.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
1,326.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
1,043.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
511.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
1,008.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
934.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-853.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
2,674.00 |
| Dec 31, 2023 |
-221,682.00 |
| Jun 30, 2023 |
-171.00 |
| Mar 31, 2023 |
-4,815.00 |
| Dec 31, 2022 |
223,204.00 |
| Sep 30, 2022 |
-6,167.00 |
| Jun 30, 2022 |
-174.00 |
| Mar 31, 2022 |
1,246.00 |
| Dec 31, 2021 |
-288,070.00 |
| Sep 30, 2021 |
3,808.00 |
| Jun 30, 2021 |
-20.00 |
| Mar 31, 2021 |
-1,162.00 |
| Jun 30, 2020 |
721.00 |
| Mar 31, 2020 |
-2,084.00 |
| Jun 30, 2019 |
-432.00 |
| Mar 31, 2019 |
-170.00 |
| Dec 31, 2018 |
-12,110.00 |
| Sep 30, 2018 |
-8,327.00 |
| Jun 30, 2018 |
-201,292.00 |
| Dec 31, 2017 |
31,463.00 |
| Sep 30, 2017 |
-3,794.00 |
| Jun 30, 2017 |
174,622.00 |
| Dec 31, 2016 |
-115,725.00 |
| Sep 30, 2016 |
-39,931,034.48 Bn |
| Mar 31, 2016 |
20.37 Bn |
| Dec 31, 2015 |
20,444.00 |
| Sep 30, 2015 |
39,931,034.48 Bn |
| Mar 31, 2015 |
-26,806.00 |
| Dec 31, 2010 |
-8.96 Bn |
| Jun 30, 2010 |
-2.64 Mn |
